Latest news with #T2D
Medscape
19 hours ago
- Health
- Medscape
Switch to Water From Diet Sodas May Boost Diabetes Remission
TOPLINE: Regularly substituting water for diet beverages contributed to greater weight loss and was associated with a twofold increase in the diabetes remission rate among women with type 2 diabetes (T2D) and obesity or overweight. METHODOLOGY: Diet sodas, despite being calorie-free, may affect the body differently from water, and their regular consumption is linked to potential health risks, including cardiovascular disease, T2D, and obesity. Researchers conducted an 18-month study to evaluate the effects of replacing diet beverages with water. The study included 81 adult women with T2D and obesity or overweight who participated in a weight-management program and regularly consumed diet beverages. Participants were randomly assigned to replace diet beverages with water or to maintain their usual intake of five diet drinks per week, consumed after lunch. All participants underwent a 6-month weight-loss program, followed by a 12-month maintenance program. TAKEAWAY: Women in the water group experienced a greater average weight loss (-6.82 ± 2.73 kg) than the diet beverage group (-4.85 ± 2.07 kg; P < .001). Diabetes remission was achieved by 90% of participants in the water group compared with 45% of those in the diet beverage group (P < .0001). Significant improvements were noted in BMI, fasting glucose, postprandial glucose, insulin, triglyceride levels, and insulin resistance in the water group. IN PRACTICE: "These findings challenge a common belief in the US that diet drinks have no potential negative effects for managing weight and blood sugar," Hamid R. Farshchi, MD, PhD, CEO of the digital platform D2Type, said in a press release. "However, with most of the women in the water group achieving diabetes remission, our study highlights the importance of promoting water, not just low-calorie alternatives, as part of effective diabetes and weight management. It's a small change with the potential for a big impact on long-term health outcomes." SOURCE: The study was led by Hamid R. Farshchi, MD, PhD, of D2Type, and former associate professor at the University of Nottingham, School of Life Sciences. It was presented as a poster on June 22, 2025, at the 85th Scientific Sessions - American Diabetes Association held at the McCormick Place Convention Center, Chicago (June 20-23, 2025). LIMITATIONS: No limitations were discussed in the press release. DISCLOSURES: No disclosures or conflict-of-interest statements were provided. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
19 hours ago
- Health
- Yahoo
Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide
MPC-inhibitor 0602K shows significant preservation of lean mass & increased muscle function combined with tirzepatide in pre-clinical DIO models 0602K shows profound beneficial transformation of adipose tissue in multiple ways & novel potential synergy with tirzepatide Both 0602K+tirzepatide and tirzepatide alone produced very similar rapid and substantial weight loss Pilot clinical study also shows 0602K by itself drives dramatic beneficial changes in muscle composition and metabolic function in patients with obesity & T2D Mitochondrial reprogramming with 0602K may add to benefits of GLP-1 weight loss with synergies in muscle & adipose tissues Data to be presented Sunday at ADA Scientific Sessions GRAND RAPIDS, Mich., June 20, 2025 /PRNewswire/ -- Cirius Therapeutics, Inc., a developer of innovative therapies for patients suffering from diseases caused by insulin resistance, including obesity/overweight and type 2 diabetes (T2D), today announced positive results from the first preclinical diet-induced obesity (DIO) studies demonstrating the potential benefits of combining 0602K and tirzepatide for patients with obesity / overweight, as well as from a pilot clinical study. Detailed data is being presented as a late-breaking poster at the American Diabetes Association's (ADA) 85th Scientific Sessions as well as a short oral presentation available online as part of the conference. "We have been advocating for the potential benefits of combining an insulin sensitizer with the latest incretin therapies, especially to more fully resolving the underlying metabolic dysfunctions in obesity, type 2 diabetes and other cardio-renal-metabolic diseases," said Dr. Ralph DeFronzo, MD, co-author and Professor of Medicine at the University of Texas Health Science Center at San Antonio. Dr. DeFronzo continued, "First generation insulin sensitizer pioglitazone has given us strong hints of the possibilities. Now, this very exciting preclinical data combining next generation insulin sensitizer 0602K with a state-of-the-art GLP-1/GIP receptor agonist, tirzepatide, further supports the enormous potential. The pilot clinical data further suggests 0602K has similar effects on body composition and metabolism in patients with obesity, and that combining the highly complementary mechanisms of 0602K and tirzepatide should drive benefits for patients beyond those already gained via weight loss." Collaborators at the Dasman Diabetes Institute in Kuwait and St. Louis University conducted parallel, independent DIO studies producing highly consistent results: Both 0602K+tirzepatide and tirzepatide alone produced very similar rapid and substantial weight loss through as long as 6 weeks treatment. 0602K + tirzepatide reduced the loss of lean mass and muscle typically seen with tirzepatide alone. Even more significantly, adding 0602K to tirzepatide increased both muscle strength and metabolic (mitochondrial) function by +50% each vs. tirzepatide alone. Adding 0602K to tirzepatide restored muscle strength/exercise capacity nearly to that of lean controls and increased mitochondrial abundance (number of mitochondria per muscle cell) by 50% over both lean controls and tirzepatide alone. 0602K + tirzepatide produced multi-faceted remodeling of adipose (fat) tissue, including reduced visceral-to-subcutaneous adipose tissue ratio (VAT:SAT), increased brown adipose tissue, and a synergistic transformation in subcutaneous adipose tissue (SAT) phenotype transformation. In SAT, 0602K and tirzepatide each produced marked decreases in adipocyte (fat cell) size, with the combination decreasing adipocyte size dramatically more than either alone. Smaller adipocytes are believed to be associated with several metabolic benefits, including an increase in numbers of "beige" adipocytes. Beige adipocytes actively consume stored fats and characteristically express uncoupling protein 1 (UCP-1), which aids in burning those fat calories. While both 0602K and tirzepatide increased UCP-1 protein in SAT by 2-3-fold over untreated high fat diet controls, the combination increased UCP1 ~7-fold with ~15% of cells UCP-1-positive. Separately, collaborators at the University of Texas Health Science Center at San Antonio conducted a small (n=3) pilot mechanistic clinical study of 0602K effects on muscle composition and metabolic function. In patients with obesity & T2D. assessed at baseline and after taking 250mg 0602K daily for 3 months: 0602K decreased intramyocellular lipid (fat inside muscle cells) by ~50% Increased muscle metabolic function (insulin-mediated glucose disposal) by ~50% Reduced HbA1c from an average of 8.33% at baseline to 6.97%. "These results support that targeting MPC with 0602K reprograms mitochondrial metabolism, not only reversing insulin resistance but also driving broad multi-organ benefits. Particularly important is 0602K synergy with GLP-1 receptor agonists we're describing here," remarked Dr. Jerry Colca, PhD, Cirius Chief Scientific Officer. Dr. Colca added, "0602K has previously been shown effective for T2D and MASH in Phase 2 clinical studies and without the side effect concerns that hung over earlier insulin sensitizers. These results highlight the need to explore the benefits of this combination particularly in patients with obesity / overweight." Cirius and several of the academic collaborators involved in the study will be available at the ADA poster (1982-LB) from 12:30-1:30 PM CDT this Sunday, June 22. Presentation Details: Title: 1982-LB - MPC-Directed Insulin Sensitizer MSDC-0602K Combines with Tirzepatide to Maintain Muscle Mass/Function and Restructure Adipose Tissue [Board No. 1982] Authors: M. Abu-Farha, J. Abubaker, F. Almulla – Dasman Diabetes Institute M. Abdul-Ghani, L. Norton, R.A. DeFronzo – University of Texas Health Sciences Center at San AntonioJ.R. Colca – Cirius TherapeuticsK.S. McCommis – St. Louis University Date & Time: Sunday, June 22, at 12:30 AM CT (poster will be up throughout meeting) Location: Poster Hall (Hall F1) About CiriusCirius is a clinical-stage pharmaceutical company focusing on mitochondrial pyruvate carrier (MPC), addressing the metabolic dysfunction that causes insulin resistance and the organ pathologies associated with type 2 diabetes (T2D) and obesity/overweight. Its lead product candidate, 0602K (azemiglitazone potassium), is a potential best-in-class novel small molecule being developed as a once-daily oral therapy designed to selectively inhibit the mitochondrial target MPC, which plays a central role in selecting mitochondrial energy substrates. MPC inhibition reprograms mitochondrial metabolism, reducing insulin resistance in cells and driving metabolic benefits in organs throughout the body. This markedly improves glycemic control in T2D, body composition in obesity, liver function and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH), and outcomes in cardiometabolic disorders. About 0602K0602K has completed 7 US clinical trials including a 52-week placebo-controlled Phase 2b study in 392 subjects with MASH with and without T2D, and a 28-day placebo-controlled Phase 2a study in 129 subjects with T2D. In those clinical studies it markedly lowered HbA1c and insulin levels, and reduced liver injury and MASH – including on top of existing GLP-1 therapy. A pilot clinical study showed 0602K markedly both reduces fat in muscle and increases muscle metabolic function in patients with obesity & T2D. Preclinical studies also demonstrate increased lean muscle mass, strength and metabolic function, together with metabolically beneficial shifts in adipose tissue phenotype ("bad fat" to "good fat"), both alone and on top of GLP-1 and GLP-1/GIP agonists. In combination with GLP-1/GIP dual agonist tirzepatide, the transformation of subcutaneous adipose tissue includes dramatic reduction in adipocyte size and synergistic increase in "beiging." Selectively targeting MPC – while avoiding PPAR-γ activation – 0602K harnesses the real-world proven efficacy of 1st generation insulin sensitizers, such as pioglitazone, but without their side effect concerns. Directly correcting a major underlying pathophysiology of chronic metabolic disease, 0602K has the potential to become a cornerstone of therapy. Coupling this potent pharmacology with that of the GLP-1s could particularly benefit patients with T2D, obesity/overweight and other cardiometabolic diseases. View original content to download multimedia: SOURCE Cirius Therapeutics
Yahoo
11-06-2025
- Health
- Yahoo
T1D Exchange Announces 13 Real-World Data Presentations and Posters at the American Diabetes Association (ADA) 85th Scientific Sessions
Studies underscore advances in screening, mental health, health equity, and early intervention in diabetes care. New study examines benefits of continuous glucose monitoring (CGM) in people with type 2 diabetes (T2D) using glucagon-like peptide-1 (GLP-1) therapy. Company strengthens leadership in type 1 diabetes (T1D) and T2D research, with more than 100 publications since 2020. BOSTON, June 11, 2025 /PRNewswire/ -- T1D Exchange, a nonprofit organization that drives meaningful research and improvement in care and outcomes in type 1 diabetes (T1D) and type 2 diabetes (T2D), today announced that new research using real-world data from its Quality Improvement Collaborative (T1DX-QI) and online patient Registry will be shared during 13 presentations at the American Diabetes Association (ADA) 85th Scientific Sessions being held June 20-23, 2025, in Chicago, Illinois. The studies highlight emerging trends and outcomes in diabetes care, including efforts to improve screening for T1D autoantibodies, technology usage, particularly CGMs, and the increased use of GLP-1 therapies by individuals with T2D. Drawing on data from the organization's Registry of more than 20,000 people with T1D, several presentations offer insights into clinical outcomes as well as the broader impact of the disease, including financial strain, mental health challenges, and comorbid conditions. A full list of abstracts being presented is available here. "We are excited to unveil impactful research driven by our growing T1DX-QI network and robust patient Registry," said David Walton, Chief Executive Officer of T1D Exchange. "By uniting over 60 endocrinology clinics, data from 150,000+ individuals with T1D and T2D, and patient-reported outcomes from people with T1D and their caregivers, we're building a collaborative, evidence-driven knowledge base to expand our capabilities, deepen datasets, and generate insights that improve care for people with diabetes." Key studies include an oral presentation exploring equitable strategies to increase CGM adoption by people with T2D, expanding on prior research in T1D: 276-OR, T1D Exchange Multicenter Study—Increasing CGM Adoption in Type 2 Diabetes on Sunday, June 22, 3:15 - 4:15 p.m. CT in Room W185 A-D Additionally, data from 12 studies will be presented during the General Poster Sessions on Saturday, June 21, Sunday, June 22, and Monday, June 23, from 12:30 - 1:30 p.m. CT in Poster Hall F1. "Many of our presentations this year highlight the strength of our engaged T1D community and the value of our growing Registry. Thousands of participants contributed to research that explores the financial, emotional, and clinical realities of living with T1D," said Wendy Wolf, PhD, Vice President of Registry and Outcomes Research at T1D Exchange. "Our Registry not only provides real-world, patient-reported insights, but also serves as a powerful platform for targeted study recruitment, enabling partners to accelerate research that is closely aligned with patient needs. Our Registry has helped recruit for dozens of research studies, including 16 clinical trials – with more than 10,000 Registry participants enrolled in external studies to date." About the T1DX-QI and the T1D Exchange RegistryThe T1D Exchange Quality Improvement Collaborative (T1DX-QI) brings together 60+ endocrinology clinics across the U.S., collectively treating more than 150,000 people living with type 1 and type 2 diabetes, to identify and address gaps in care and accelerate evidence-based, practical solutions. Participating clinics contribute anonymized patient data and insights from their respective clinics, expanding the collective knowledge base and creating a unified data asset to expedite improvements in care for all people living with type 1 and type 2 diabetes. The T1D Exchange Registry is an online longitudinal study that tracks disease progress and gathers information directly from people with type 1 diabetes and caregivers of children with type 1 diabetes. To date, the Registry includes over 20,000 participants in the U.S. These individuals share patient-reported outcomes, including data on disease management. Participants update their information annually, participate in internal research projects, and are connected to external curated research opportunities, including clinical trials. The online Registry is designed to lower barriers to participating in diabetes research, including patient populations often underrepresented in clinical studies. The T1DX-QI and T1D Exchange Registry have contributed to more than 100 publications by T1D Exchange in leading medical journals since 2020. About T1D ExchangeT1D Exchange is a leader in harnessing data to advance diabetes care and outcomes by driving collaborative change. Through real-world evidence and clinical data collection and analysis, its programs provide novel insights that identify gaps in care and refine best practices to improve the lives of those living with diabetes. T1D Exchange supports quality improvement and innovation through its Quality Improvement Collaborative (T1DX-QI), online patient Registry, and data-oriented research services. Through a knowledge-sharing and collaboration-focused approach, T1D Exchange accelerates real-world impact by providing clinicians, researchers, industry partners, and advocates with the resources and services they need for better decision support and population health management. T1D Exchange is a nonprofit organization established in 2010 with ongoing support from The Leona M. and Harry B. Helmsley Charitable Trust. To learn more about T1DX-QI member clinics, click here. For more information on the Registry, visit Media Contact:Suzanne McKeeDirector of Marketing, T1D ExchangePhone: 617-671-0429Email: smcKee@ View original content to download multimedia: SOURCE T1D Exchange
Medscape
05-06-2025
- Health
- Medscape
Novel Survey Effectively Screens Binge Eating in Diabetes
A new diabetes-specific 10-item screening tool demonstrated excellent performance in detecting binge eating disorder in both patients with type 1 diabetes (T1D) and those with type 2 diabetes (T2D), showing strong associations with glycaemic control and mental health outcomes. METHODOLOGY: Although diabetes-specific screening for disordered eating behaviours is advised, the only available tool — the Diabetes Eating Problem Survey–Revised (DEPS-R) — is tailored for patients with T1D on rapid-acting insulin therapy, limiting its applicability across other diabetes types and treatment regimens. Researchers developed a 10-item non–insulin-specific version of the DEPS-R (DEPS-10) and evaluated its screening performance for binge eating disorder in 679 patients with T1D or T2D (mean age, 53.8 years) who had the disease for at least 1 year. The new survey assessed loss of control over eating, dietary and purging behaviours, and challenges in diabetes management. Researchers conducted a receiver operating characteristic curve analysis to test the screening performance of the DEPS-10 and compared it with those of the original DEPS-R and the Problem Areas In Diabetes (PAID) scale. TAKEAWAY: The point prevalence of binge eating disorder was 3.5% in the whole cohort, 2.9% in patients with T1D, and 4.3% in those with T2D. The DEPS-10 showed excellent screening performance for binge eating disorder (area under the curve [AUC], 0.92; P < .001), matching that of the DEPS-R (AUC, 0.92; P < .001) and surpassing that of the PAID scale (AUC, 0.82; P < .001). < .001), matching that of the DEPS-R (AUC, 0.92; < .001) and surpassing that of the PAID scale (AUC, 0.82; < .001). The DEPS-10 showed optimal sensitivity (87.5%) and specificity (86.9%) for detecting binge eating disorder at a cutoff score of greater than or equal to 15; participants with this cutoff score had higher body mass index and A1c level along with a greater psychological burden than those with scores below it. The stepwise approach of first screening with the PAID scale and then applying the DEPS-10 boosted specificity to 94%, compared with 87% when using the DEPS-10 alone and 67% when using the PAID scale alone. IN PRACTICE: "A two-step approach using the PAID followed by the DEPS-10 can be a feasible and time-efficient procedure in routine care," the authors wrote. SOURCE: This study was led by Laura Yvonne Klinker, Diabetes Center Mergentheim in Bad Mergentheim, Germany. It was published online on May 29, 2025, in Diabetic Medicine . LIMITATIONS: Higher DEPS-10 scores in one fifth of the participants may have been affected by glucagon-like peptide 1 therapy. Additionally, the relatively low positive predictive value of the DEPS-10 could have been attributed to its broader scope in detecting various disordered eating behaviours beyond binge eating disorder. DISCLOSURES: This study was funded by a grant from the German Center for Diabetes Research. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. References Credit Lead image: Anastasiia Torianyk/Dreamstime Medscape News UK © 2025 WebMD, LLC Cite this: Novel Survey Effectively Screens Binge Eating in Diabetes - Medscape - June 05, 2025.
Medscape
28-05-2025
- General
- Medscape
NICU Admissions Higher in Pregestational Diabetes
Neonatal intensive care unit (NICU) admission rates were significantly higher among infants born to mothers with pregestational diabetes than among those born to mothers with gestational diabetes (GD). METHODOLOGY: This Irish study compared risks for NICU admission across maternal diabetes subtypes (type 1 diabetes [T1D], type 2 diabetes [T2D], and GD) to refine counselling and neonatal care. Researchers conducted a retrospective analysis of 25,238 births (January 2018 to December 2020) and identified 3905 neonates born ≥ 34 weeks to mothers with diabetes, including those with T1D (n = 67), T2D (n = 60), and GD (n = 3712). Data on gestational age, birth weight, mode of delivery, and maternal age were extracted from the registry. NICU admission details (indications, hypoglycaemia, and respiratory support) and maternal characteristics (body mass index [BMI] > 30 and preeclampsia) were obtained via electronic records. The analysis was performed using quasi-Poisson regression for assessing NICU admission risk ratios (RRs), analysis of variance for comparing gestational age/birth weight, and chi-square tests for comparing categorical variables. The primary outcome was the NICU admission rate; secondary outcomes included respiratory distress, severe hypoglycaemia, and maternal discharge timing. TAKEAWAY: Neonates born to mothers with T1D and T2D had a admission rate of 41.8% (RR, 3.32) and 31.1% (RR, 3.89), respectively, with both significantly higher than that in those born to mothers with GD (12.5%; RR, 0.133; P ≤ .001); the hospital baseline admission rate was 11.5%. ≤ .001); the hospital baseline admission rate was 11.5%. Neonates of mothers with T1D were born earlier (mean, 37 + 1 weeks) than those of mothers with T2D (mean, 38 + 1 weeks; P = .0019) and GD (mean, 39 weeks; P ≤ .001). = .0019) and GD (mean, 39 weeks; ≤ .001). Moreover, they showed significantly higher birth weight centiles than those of mothers with T2D and GD at 25th (T1D vs T2D, P = .0042; T1D vs GD, P ≤ .001), median ( P ≤ .0001 for both), and 75th centiles (T1D vs T2D, P ≤ .0001; T1D vs GD, P = .0009). = .0042; T1D vs GD, ≤ .001), median ( ≤ .0001 for both), and 75th centiles (T1D vs T2D, ≤ .0001; T1D vs GD, = .0009). Respiratory distress dominated T1D admissions (36.7%), while hypoglycaemia was primary in T2D (73.7%). Mothers with pregestational diabetes were more frequently discharged before their infants (T1D, 42.9%; T2D, 31.5%) than those with GD (21.2%). IN PRACTICE: "It is important to counsel mothers on risks and expectations for the newborn period," the authors of the study wrote. "The aim of our study is to describe how the type of maternal diabetes impacts admission to NICU and to provide up-to-date, local data to support healthcare professionals when counselling patients with diabetes in pregnancy," they added. SOURCE: This study was led by Dearbhla Hillick, Rotunda Hospital, Dublin, Ireland. It was published online on May 22, 2025, in the European Journal of Pediatrics . LIMITATIONS: This study was limited by the dataset being unbalanced, with most neonates born to mothers with GD. Neonates of mothers without diabetes requiring NICU admission were not included. Factors such as maternal smoking, raised BMI, or preeclampsia possibly confounded the NICU admission risk. DISCLOSURES: Open access funding was provided by the IReL Consortium. The authors reported having no relevant conflicts of interest.
